OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
VCEL
Vericel Corporation
VCEL has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VCEL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
VCEL's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over VCEL in the historical PE scenario, which offers more potential upside but is not a forecast.
VCEL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 67x | $57.42 | — |
| Current | 88x | $57.42 | — |
| Cheap | 106x | $68.69 | +20% |
| Fair | 277x | $180 | +214% |
| Expensive | 1,180x | $767 | +1236% |
Historical ranges are pointers, not guarantees.
VCEL's PE is in its cheap range at 88x. If earnings grow as analysts expect, today's price would be 67x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VCEL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for VCEL, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
VCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.86 | +32% |
| Q3 2026 | $0.65 | +150% |
| Q2 2026 | $0.48 | +243% |
| Q1 2026 | $0.43 | +760% |
| Q4 2025 | $0.32 | +60% |
| Q3 2025 | $0.26 | +225% |
| Q2 2025 | $0.14 | +600% |
| Q1 2025 | $0.05 | +400% |
| Q4 2024 | $0.20 | +$0.27 |
VCEL has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VCEL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
VCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $85.4M | +26% |
| Q2 2026 | $77.5M | +22% |
| Q1 2026 | $68.4M | +30% |
| Q4 2025 | $92.9M | +23% |
| Q3 2025 | $67.5M | +17% |
| Q2 2025 | $63.2M | +20% |
| Q1 2025 | $52.6M | +2.6% |
| Q4 2024 | $75.4M | +16% |
VCEL's revenue has grown year over year for 17 quarters in a row: $85M last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +9.2 points |
| Q2 2026 | 0.6% | +3.8 points |
| Q1 2026 | -12% | +13 points |
| Q4 2025 | 24% | -0.4 points |
| Q3 2025 | 5.1% | +9.4 points |
| Q2 2025 | -3.2% | +8.2 points |
| Q1 2025 | -24% | -14 points |
| Q4 2024 | 25% | +4.9 points |
VCEL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VCEL on cash flow, with more consistent year-over-year improvement.
VCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.7M | -19% |
| Q2 2026 | $14.3M | +17504% |
| Q1 2026 | $15.1M | +$22.7M |
| Q4 2025 | $12.8M | +52% |
| Q3 2025 | $19.5M | +$28.7M |
| Q2 2025 | $81K | -95% |
| Q1 2025 | -$7.6M | -$797K |
| Q4 2024 | $8.5M | +276% |
VCEL generated $58M in free cash flow over the past year, up 184% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +650K shares |
| 1 year | +2% | +1.1M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +13% | +6.3M shares |
| Available history | +20% | +8.8M shares |
VCEL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over VCEL on leverage, with a lower net debt burden relative to earnings.
VCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.3x | Net Cash |
| Q2 2026 | -4.0x | Net Cash |
| Q1 2026 | -3.9x | Net Cash |
| Q4 2025 | -4.4x | Net Cash |
| Q3 2025 | -5.9x | Net Cash |
| Q2 2025 | -8.5x | Net Cash |
| Q1 2025 | -18.4x | Net Cash |
| Q4 2024 | -7.4x | Net Cash |
VCEL has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.1 | Overbought |
| Stochastic | 69.5 | Neutral |
VCEL's weekly RSI is 75 (overbought) and its Stochastic is 70 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over VCEL on valuation relative to its sector.
VCEL PE vs Healthcare Sector
| Metric | VCEL | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 242% above |
| PE % | 10 | 29 | 19 pts below |
VCEL is trading at 88x earnings, a 242% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
VCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.4 | 29% above |
| 20 week MA | $43.9 | 31% above |
| 50 week MA | $39.0 | 47% above |
| 100 week MA | $41.0 | 40% above |
| 200 week MA | $40.5 | 42% above |
VCEL is in an uptrend: it's above all five of its weekly moving averages, and 42% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VCEL on returns for 2026, with the stronger performance.
VCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.5 | $29.0 | +66% |
| 2021 | $29.0 | $41.6 | +44% |
| 2022 | $41.6 | $23.8 | -43% |
| 2023 | $23.8 | $35.6 | +49% |
| 2024 | $35.6 | $57.3 | +61% |
| 2025 | $57.3 | $37.7 | -34% |
| 2026 YTD | $37.7 | $57.4 | +52% |
VCEL has finished higher in four of the last six years, two of them by more than 50%. It's up 52% so far in 2026.